Trial Profile
Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 23 Jul 2015 Primary endpoints been amended.
- 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov reccord.
- 12 Jan 2012 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.